Alcobra Ltd. (ADHD) - NASDAQ
Company Description
Alcobra Ltd. engages in the development and commercialization of proprietary pharmaceutical products for the treatment of central nervous system disorders and cognitive dysfunctions. Its proprietary oral drug candidate, Metadoxine Extended Release, to treat Attention Deficit Hyperactivity... More
Sector: Healthcare
Industry: Drug Related Products
Country: Israel